[10-Q] UNITED GUARDIAN INC Quarterly Earnings Report
United-Guardian (UG) filed its Q3 2025 10-Q reporting lower sales and earnings. Net sales were $2,264,261, down from $3,060,113 a year ago, with nine‑month sales at $7,583,613 versus $9,705,262. Net income was $268,441 in the quarter (vs. $865,484) and $1,456,162 year‑to‑date (vs. $2,747,151). EPS was $0.06 for the quarter (vs. $0.19) and $0.32 year‑to‑date (vs. $0.60).
Mix and volume pressures weighed on margins: cost of sales rose to 58% of sales in Q3 (46% prior year) and to 50% for the nine months (47% prior year), reflecting a higher contribution from lower‑margin pharmaceuticals and lower cosmetic volumes. Cosmetic ingredient sales softened, particularly tied to China demand and tariff dynamics, while pharmaceuticals grew on both a gross and net basis.
Operating cash flow was $1,636,324 for the nine months. The company paid cash dividends of $0.35 per share in February and $0.25 per share in August. Management highlighted ongoing tariff uncertainty related to China and noted the Natrajel launch timing has shifted to 2026 due to customer timelines. Working capital remains strong with a 7.0:1 current ratio.
- None.
- Sales and earnings decline: Q3 net sales fell to $2.26M (from $3.06M) and EPS to $0.06 (from $0.19); nine‑month sales were $7.58M (from $9.71M) and EPS $0.32 (from $0.60).
- Margin pressure: Cost of sales rose to 58% of sales in Q3 and 50% year‑to‑date due to lower cosmetic volumes and a shift toward lower‑margin pharmaceuticals.
- China tariff exposure: Filing cites ongoing tariff uncertainty and softer China‑linked cosmetic demand impacting 2025 sales.
Insights
Earnings fell on weaker cosmetics and mix shift to lower-margin pharma.
UG posted Q3 net sales of
Tariff exposure is a key variable. The text notes reliance on shipments into China and ongoing U.S.–China tariff discussions. This can pressure pricing and volumes, especially for cosmetics, and the company indicates the impact was reflected in 2025 sales. The Natrajel sexual wellness line is now expected to begin manufacturing in
Cash generation remained positive at
U.S. SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
(Mark One)
|
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended
|
|
TRANSITION REPORT PURSUANT TO 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from ________ to ________
COMMISSION FILE NUMBER:
(Exact Name of Registrant as Specified in Its Charter)
|
|
|
|
(State or Other Jurisdiction of |
(I.R.S. Employer Identification No.) |
|
Incorporation or Organization) |
(Address of Principal Executive Offices)
(
(Registrant’s Telephone Number)
N/A
(Former name, former address, and former fiscal year, if changed since last report)
Cover Page 1 of 2
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class |
Trading Symbol |
Name of each exchange on which registered |
|
|
|
|
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act.
|
Large accelerated filer ☐ |
Accelerated filer ☐ |
|
|
Smaller reporting company |
|
Emerging growth company |
If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act.) Yes
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date:
As of November 1, 2025, the Registrant had issued and outstanding
Cover Page 2 of 2
UNITED-GUARDIAN, INC.
INDEX TO FINANCIAL STATEMENTS
| Page No. | |
|
Part I. FINANCIAL INFORMATION |
|
|
Item 1 - Condensed Financial Statements (unaudited unless indicated otherwise) |
2 |
|
Statements of Income - Three and Nine Months ended September 30, 2025 and 2024 |
2 |
|
Balance Sheets – September 30, 2025 (unaudited) and December 31, 2024 (audited) |
3 - 4 |
|
Statements of Changes in Stockholders’ Equity – Three and Nine Months ended September 30, 2025 and 2024 |
5 |
|
Statements of Cash Flows - Nine Months ended September 30, 2025 and 2024 |
6 |
|
Notes to Condensed Financial Statements |
7 - 19 |
|
Item 2 - Management's Discussion and Analysis of Financial Condition and Results of Operations |
19 - 24 |
|
Item 3 - Quantitative and Qualitative Disclosures About Market Risk |
24 |
|
Item 4 - Controls and Procedures |
24 - 25 |
|
Part II. OTHER INFORMATION |
|
|
Item 1 - Legal Proceedings |
25 |
|
Item 1A - Risk Factors |
25 -26 |
|
Item 2 - Unregistered Sales of Equity Securities and Use of Proceeds |
26 |
|
Item 3 - Defaults Upon Senior Securities |
26 |
|
Item 4 - Mine Safety Disclosures |
26 |
|
Item 5 - Other Information |
27 |
|
Item 6 - Exhibits |
27 |
|
Signatures |
28 |
UNITED-GUARDIAN, INC.
Part I. FINANCIAL INFORMATION
ITEM 1. Condensed Financial Statements
STATEMENTS OF INCOME
(UNAUDITED)
|
THREE MONTHS ENDED |
NINE MONTHS ENDED SEPTEMBER 30, |
|||||||||||||||
|
2025 |
2024 |
2025 |
2024 |
|||||||||||||
|
Net sales |
$ | $ | $ | $ | ||||||||||||
|
Costs and expenses: |
||||||||||||||||
|
Cost of sales |
||||||||||||||||
|
Operating expenses |
||||||||||||||||
|
Research and development expense |
||||||||||||||||
|
Total costs and expenses |
||||||||||||||||
|
Income from operations |
||||||||||||||||
|
Other Income: |
||||||||||||||||
|
Investment income |
||||||||||||||||
|
Net gain on marketable securities |
||||||||||||||||
|
Total other income |
||||||||||||||||
|
Income before provision for income taxes |
||||||||||||||||
|
Provision for income taxes |
||||||||||||||||
|
Net income |
$ | $ | $ | $ | ||||||||||||
|
Earnings per common share (Basic and Diluted) |
$ | $ | $ | $ | ||||||||||||
|
Weighted average shares (Basic and Diluted) |
||||||||||||||||
See Notes to Condensed Financial Statements
UNITED-GUARDIAN, INC.
BALANCE SHEETS
ASSETS
| SEPTEMBER 30, | DECEMBER 31, | |||||||
|
2025 |
2024 |
|||||||
|
(UNAUDITED) |
(AUDITED) |
|||||||
|
Current assets: |
||||||||
|
Cash and cash equivalents |
$ | $ | ||||||
|
Marketable securities |
||||||||
|
Accounts receivable, net of allowance for credit losses of $ |
||||||||
|
Inventories, net |
||||||||
|
Prepaid expenses and other current assets |
||||||||
|
Prepaid income taxes |
||||||||
|
Total current assets |
||||||||
|
Deferred income taxes (net) |
||||||||
|
Net property, plant, and equipment: |
||||||||
|
Land |
||||||||
|
Factory equipment and fixtures |
||||||||
|
Building and improvements |
||||||||
|
Total property, plant, and equipment |
||||||||
|
Less: Accumulated depreciation |
||||||||
|
Total property, plant, and equipment, net |
||||||||
|
TOTAL ASSETS |
$ | $ | ||||||
See Notes to Condensed Financial Statements
UNITED-GUARDIAN, INC.
BALANCE SHEETS
(continued)
LIABILITIES AND STOCKHOLDERS’ EQUITY
| SEPTEMBER 30, | DECEMBER 31, | |||||||
|
2025 |
2024 |
|||||||
|
Current liabilities: |
(UNAUDITED) |
(AUDITED) |
||||||
|
Accounts payable |
$ | $ | ||||||
|
Accrued expenses |
||||||||
|
Dividends payable |
||||||||
|
Total current liabilities |
$ | $ | ||||||
|
Total liabilities |
$ | $ | ||||||
|
Commitments and contingencies |
|
|
||||||
|
Stockholders’ equity: |
||||||||
|
Common stock (at $.10 par value) ( |
||||||||
|
Retained earnings |
||||||||
|
Total stockholders’ equity |
||||||||
|
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY |
$ | $ | ||||||
See Notes to Condensed Financial Statements
UNITED-GUARDIAN, INC.
STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY
THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2025
|
Common stock |
Retained | |||||||||||||||
| Shares | Amount | Earnings | Total | |||||||||||||
|
Balance, January 1, 2025 |
$ | $ | $ | |||||||||||||
|
Net income |
- | - | ||||||||||||||
|
Dividends declared and paid ($ |
- | ( |
) | ( |
) | |||||||||||
|
Dividends declared, not paid ($ |
- | ( |
) | ( |
) | |||||||||||
|
Balance, March 31, 2025 |
$ | $ | $ | |||||||||||||
|
Net income |
- | |||||||||||||||
|
Balance, June 30, 2025 |
$ | $ | $ | |||||||||||||
|
Net income |
- | |||||||||||||||
|
Dividends declared and paid ($ |
- | ( |
) | ( |
) | |||||||||||
|
Dividends declared, not paid ($ |
- | ( |
) | ( |
) | |||||||||||
|
Balance, September 30, 2025 |
$ | $ | $ | |||||||||||||
THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2024
|
Common stock |
Retained | |||||||||||||||
| Shares | Amount | Earnings | Total | |||||||||||||
|
Balance, January 1, 2024 |
$ | $ | $ | |||||||||||||
|
Net income |
- | |||||||||||||||
|
Dividends declared and paid ($ |
- | ( |
) | ( |
) | |||||||||||
|
Dividends declared, not paid ($ |
- | ( |
) | ( |
) | |||||||||||
|
Balance, March 31, 2024 |
$ | $ | $ | |||||||||||||
|
Net income |
- | |||||||||||||||
|
Balance, June 30, 2024 |
$ | $ | $ | |||||||||||||
|
Net income |
- | |||||||||||||||
|
Dividends declared and paid ($ |
- | ( |
) | ( |
) | |||||||||||
|
Dividends declared, not paid ($ |
- | ( |
) | ( |
) | |||||||||||
|
Balance, September 30, 2024 |
$ | $ | $ | |||||||||||||
See Notes to Condensed Financial Statements
UNITED-GUARDIAN, INC.
STATEMENTS OF CASH FLOWS
(UNAUDITED)
|
NINE MONTHS ENDED |
||||||||
|
SEPTEMBER 30, |
||||||||
|
Cash flows from operating activities: |
2025 |
2024 |
||||||
|
Net income |
$ | $ | ||||||
|
Adjustments to reconcile net income to net cash provided by operating activities: |
||||||||
|
Depreciation and amortization |
||||||||
|
Net gain on marketable securities |
( |
) |
( |
) | ||||
|
Allowance for credit losses |
( |
) | ||||||
|
Change in allowance for obsolete inventory |
( |
) | ( |
) | ||||
|
Deferred income taxes |
( |
) | ||||||
|
Decrease (increase) in operating assets: |
||||||||
|
Accounts receivable |
||||||||
|
Inventories |
||||||||
|
Prepaid expenses and other current assets |
||||||||
|
Prepaid income taxes |
( |
) | ||||||
|
(Decrease) increase in operating liabilities: |
||||||||
|
Accounts payable |
( |
) | ||||||
|
Accrued expenses |
( |
) | ( |
) | ||||
|
Deferred revenue |
( |
) | ||||||
|
Net cash provided by operating activities |
||||||||
|
Cash flows from investing activities: |
||||||||
|
Acquisition of property, plant and equipment |
( |
) |
( |
) |
||||
|
Proceeds from sale of marketable securities |
||||||||
|
Purchases of marketable securities |
( |
) | ( |
) | ||||
|
Net cash provided by (used in) investing activities |
( |
) | ||||||
|
Cash flows from financing activities: |
||||||||
|
Dividends paid |
( |
) |
( |
) | ||||
|
Net cash used in financing activities |
( |
) |
( |
) | ||||
|
Net decrease in cash and cash equivalents |
( |
) | ( |
) | ||||
|
Cash and cash equivalents at beginning of period |
||||||||
|
Cash and cash equivalents at end of period |
$ | $ | ||||||
|
Supplemental disclosure of cash flow information: |
||||||||
|
Taxes paid |
$ | $ | ||||||
|
Supplemental disclosure of non-cash items: |
||||||||
|
Dividends payable |
$ | $ | ||||||
See Notes to Condensed Financial Statements
UNITED-GUARDIAN, INC.
NOTES TO CONDENSED FINANCIAL STATEMENTS
(UNAUDITED)
|
1. |
Business |
United-Guardian, Inc. (“Company”) is a Delaware corporation that, through its Guardian Laboratories division, manufactures, markets and develops specialty cosmetic ingredients, notably a line of Lubrajel® hydrogels, pharmaceutical products, medical lubricants and sexual wellness ingredients. In October 2023, the Company entered into a distribution agreement with Brenntag Specialties, a global market leader in chemicals and ingredients distribution, for the distribution of the Company’s new Natrajel® line of sexual wellness ingredients in the United States, Canada, Mexico, Central America and South America. We had expected to begin manufacturing and reporting sales of this new line of products in 2025, but manufacturing has been delayed until 2026 due to customer launch timeline.
The Company conducts various Research and Development (“R&D”) activities. Our R&D department primarily develops new and unique specialty cosmetic and sexual wellness ingredients. We also develop new medical lubricants for our medical customers. The Company develops new products using natural and environmentally friendly raw materials, which is a priority for many of our cosmetic customers. Our R&D department also modifies, refines, and expands the uses for existing products, with the goal of further developing the markets that our products are used in. All the products that we market, except for Renacidin®, are produced at our facility in Hauppauge, New York. Renacidin, a urological irrigation solution, is manufactured for us by an outside contract manufacturer.
|
2. |
Basis of Presentation |
Interim condensed financial statements of the Company are prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”) for interim financial information, pursuant to the requirements for reporting on Form 10-Q and Regulation S-X. In the opinion of management, all adjustments considered necessary for the fair presentation of financial statements for the interim periods have been included. The results of operations for the three and nine months ended September 30, 2025 (also referred to as the "third quarter of 2025" and the "first nine months of 2025," respectively) are not necessarily indicative of results that ultimately may be achieved for any other interim period or for the year ending December 31, 2025. The interim unaudited condensed financial statements and notes thereto should be read in conjunction with the audited financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024.
|
3. |
Segment Information |
The Company operates its business under one operating segment, which is also its reportable segment. The Company's chief operating decision maker (“CODM”), who is the President, reviews financial information presented at the consolidated level and decides how to allocate resources based on financial metrics, including net income. The measure of segment assets is reported on the balance sheet as total consolidated assets. The CODM, along with our Board of Directors, use such financial metrics, including net income, to evaluate income generated from segment assets (return on assets) in deciding whether to reinvest profits or allocate them to other parts of the organization, such as working capital needs, mandatory and discretionary capital expenditures or other growth opportunities that may arise that are in our best interest and the best interest of our stockholders.
Net income, other financial metrics and sales forecasts are used to monitor budget versus actual results. The reported segment revenue, segment profit or loss and significant segment expenses are the same as the consolidated results disclosed on the consolidated statements of income.
|
4. |
Impact of Global Supply Chain Instability, Inflation and Tariffs |
The Company is actively monitoring trade policy and tariff announcements including executive orders issued by the executive branch of the United States (“U.S.”) federal government regarding tariffs on imports from various countries, with a focus on China, as these tariffs and any reciprocal actions by the Chinese government could have the greatest potential to significantly impact our business. We are also monitoring the potential impact of actions taken by other countries in response to the announced tariffs. While many countries have reached agreements with the U.S., China announced on August 12, 2025 that they have agreed to maintain their retaliatory tariff rate at 10% until November 10, 2025. Based on a recent meeting between the U.S. and China, negotiations for a one-year truce has been established which lowers the tariffs imposed on China but it is unclear if the retaliatory tariff will be modified. We are still in discussions with one of our distributors on how we may be able to help mitigate the financial impact of their shipments of our products into China. These discussions are ongoing and subsequently may change based on the outcome of the U.S. and China negotiations; however no definitive agreement has been reached at this time. It is also unclear at this time if additional retaliatory tariffs will be imposed and what impact they will have on our business. We will continue to monitor the situation closely.
A significant amount of our cosmetic ingredient and medical lubricant sales are reliant on shipments to China. If significant tariffs or other restrictions are placed on Chinese imports, or any countermeasures are taken by China, our business, financial condition or results of operations could be materially and adversely affected. Such tariffs may make our products less cost competitive and reduce gross margins, especially in China, where we face significant competition from Asian companies that manufacture and sell products that are competitive with our products. Furthermore, we may not be able to increase our prices for our products enough to offset these tariffs, and if we raise prices in response to these tariffs, demand for our products in certain regions may be reduced. The impact of the softened demand in China due to these tariffs was reflected in the sales of our cosmetic products during the first nine months of 2025.
Many of our products are used in the formulation of finished products that are manufactured in China and then imported back into the U.S. for sale. There is the possibility that the tariffs levied on these finished products could result in an increase in their price, which could potentially impact demand for these products in the U.S. There is also a possibility that customers will consider moving their manufacturing from China as a strategic decision to limit the impact from tariffs. We have strong global relationships with our distributors and will continue to work together to understand how tariffs are impacting their business.
We source products through numerous suppliers, many of whom have established long-term relationships with us. While we obtain most of our raw materials and lab supplies from domestic sources, we have three suppliers that obtain their raw materials from China. These materials are not purchased by us in large quantities, and we have adequate stock on hand to cover the next six months. In addition, we have one direct raw material supplier in China; however, we do not purchase large quantities of raw materials from this supplier, and the effect of this tariff would not materially impact the pricing of our products.
At this time, the overall impact on our business related to these or any other tariffs that may be imposed, remains uncertain and depends on multiple factors, including the duration and expansion of current tariffs, future changes to tariff rates, scope or enforcement, retaliatory measures by impacted trade partners, inflationary effects, and the effectiveness of our responses in managing these challenges.
|
5. |
Use of Estimates |
In preparing financial statements in conformity with US GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as revenues and expenses during the reporting period. Actual results could differ from those estimates. Such estimated items include the reserve for credit losses, reserve for inventory obsolescence, accrued distribution fees, outdated material returns, possible impairment of marketable securities, and the allocation of overhead.
|
6. |
Cash and Cash Equivalents |
For financial statement purposes, the Company considers as cash equivalents all highly liquid investments with an original maturity of three months or less at the time of purchase. The Company deposits cash and cash equivalents with financially strong, Federal Deposit Insurance Corporation (“FDIC”) insured financial institutions, and it believes that any amounts above FDIC insurance limitations are at minimal risk. The amounts held in excess of FDIC limits at any point in time are considered temporary and are primarily due to the timing of maturities of United States (“U.S.”) Treasury Bills. Cash and cash equivalents held in these accounts are currently insured by the FDIC up to a maximum of $250,000. At September 30, 2025 and December 31, 2024, $
The following table summarizes the Company's cash and cash equivalents:
| September 30, | December 31, | |||||||
| 2025 | 2024 | |||||||
|
Demand deposits |
$ | $ | ||||||
|
Money market funds |
||||||||
|
Total cash and cash equivalents |
$ | $ | ||||||
|
7. |
Accounts Receivable and Reserves |
In accordance with FASB ASC Topic 326, “Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments”, (“ASC 326”), the Company presents financial assets at the net amount expected to be collected, requiring immediate recognition of estimated credit losses expected to occur over the asset’s remaining life. This is in contrast to previous U.S. GAAP, under which credit losses were not recognized until it was probable that a loss had been incurred. The Company performed its expected credit loss calculation based on historical accounts receivable write-offs, including consideration of then-existing economic conditions and expected future conditions. The adoption of this ASU did not have a significant impact on the financial statements. Prior to the implementation of ASU No. 2016-13, the Company calculated a reserve for accounts receivable by considering many factors including historical data, experience, customer types, credit worthiness and economic trends.
The carrying amount of accounts receivable is reduced by an allowance for credit losses that reflects the Company’s best estimate of the amounts that will not be collected as of the balance sheet date. This allowance is based on the credit losses expected to arise over the life of the asset and is based on the Current Expected Credit Losses (“CECL”). At September 30, 2025, and December 31, 2024, the allowance for credit losses related to accounts receivable amounted to $
|
8. |
Revenue Recognition |
The Company records revenue in accordance with ASC Topic 606 “Revenue from Contracts with Customers.” Under this guidance, revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration expected to be received in exchange for those goods or services. Our principal source of revenue is product sales.
Our sales, as reported, are subject to a variety of deductions, some of which are estimated. These deductions are recorded in the same period in which the revenue is recognized. Such deductions, primarily related to the sale of our pharmaceutical products, include chargebacks from the United States Department of Veterans Affairs (“VA”), rebates in connection with our current participation in Medicare programs, distribution fees, discounts, and outdated product returns. These deductions represent estimates of the related obligations and, as such, knowledge and judgment are required when estimating the impact of these revenue deductions on sales for a reporting period.
During 2025 and 2024, we participated in various government drug rebate programs related to the sale of Renacidin, our most important pharmaceutical product. These programs include the Veterans Affairs Federal Supply Schedule (“FSS”), and the Medicare Part D Manufacturer Discount Program (“MDP”), (formerly the Medicare Part D Coverage Gap Discount Program (“CGDP”)). These programs require us to sell our products at a discounted price, typically in the form of a rebate. Our sales, as reported, are net of these rebates, some of which are estimated and are recorded in the same period that the revenue is recognized.
On January 1, 2025, the Centers for Medicare & Medicaid Services (“CMS”) implemented a new Medicare Part D Manufacturer Discount Program (“Discount Program”), which replaced the prior CGDP. The new Discount Program eliminates the coverage gap benefit phase, introduces pharmaceutical manufacturer discounts in the initial and catastrophic coverage phases, and lowers the cap on enrollee out-of-pocket costs. Under the new Discount Program, additional rebates are expected to be owed by pharmaceutical manufacturers due to the restructuring of the benefit periods and removal of the cap that was in place that limited the drug manufacturer’s liability. The overall financial impact of this new program will vary depending on the products being reimbursed but it is expected to increase Medicare Part D rebates for drug manufacturers.
On January 31, 2024, we were notified by CMS that we qualified as a “specified small manufacturer” and would be entitled to a multi-year phase-in period during which we would pay a lower percentage discount on drugs dispensed to beneficiaries. Based on our “specified small manufacturer” designation, it appears, based on our current level of sales through the Medicare Part D Program, we would have reduced rebate liabilities in years 2025 and 2026, with rebates gradually increasing each year thereafter, until they reach their full phase-in by 2031. By the end of the phase in period in 2031, these rebate liabilities are expected to significantly exceed the liabilities we have recorded under the CGDP in previous years.
As long as a valid purchase order has been received and future collection of the sale amount is reasonably assured, we recognize revenue from sales of our products when those products are shipped, which is when our performance obligation is satisfied. Our cosmetic products are shipped EXW from our facility in Hauppauge, NY, and the risk of loss and responsibility for the shipment passes to the customer upon shipment. Sales of our medical lubricant products are deemed final upon shipment, and we have no obligation to repurchase or allow the return of these goods unless they are defective. Sales of our pharmaceutical products are final upon shipment unless (a) they are found to be defective; (b) the product is damaged in shipping; (c) the product is too close to its expiration date for the customer to sell; or (d) the product is expired but is not more than one year after its expiration date. These return policies are in conformance with standard pharmaceutical industry practice. We estimate an allowance for outdated material returns based on previous years’ historical returns of our pharmaceutical products.
The Company does not make sales on consignment, and the collection of the proceeds of the sale of any of our products is not contingent upon the customer being able to sell the goods to a third party.
Any allowances for returns are taken as a reduction of sales within the same period the revenue is recognized. Such allowances are determined based on historical experience under ASC Topic 606. We have not experienced significant fluctuations between estimated allowances and actual activity.
The Company has distribution fee contracts with certain distributors of its pharmaceutical products that entitle them to distribution and service-related fees. The Company records distribution fees and estimates of distribution fees as offsets to revenue.
Disaggregated sales by product class are as follows:
| Three months ended | Nine months ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
|
Cosmetic ingredients |
$ | $ | $ | $ | ||||||||||||
|
Pharmaceutical |
||||||||||||||||
|
Medical lubricants |
||||||||||||||||
|
Total Sales |
$ | $ | $ | $ | ||||||||||||
The Company’s cosmetic ingredients are marketed worldwide by five distributors, of which U.S.-based Ashland Specialty Ingredients (“ASI”) purchases the largest volume. Approximately
Disaggregated sales by geographic region are as follows:
| Three months ended | Nine months ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
|
United States* |
$ | $ | $ | $ | ||||||||||||
|
Other countries |
||||||||||||||||
|
Total Sales |
$ | $ | $ | $ | ||||||||||||
* Substantially all purchases by ASI are shipped to ASI’s warehouses in the U.S. As a result, all sales to ASI are reported as U.S. sales for financial reporting purposes, even though a significant quantity of those purchases will be shipped by ASI to foreign customers. ASI has reported to the Company that approximately
For the nine months ended September 30, 2025 approximately
|
9. |
Accounting for Financial Instruments – Credit Losses |
The Company recognizes an allowance for credit losses for its trade receivables to present the net amount expected to be collected as of the balance sheet date. This allowance is based on the credit losses expected to arise over the life of the asset and are based on Current Expected Credit Losses (CECL).
The Company performs ongoing credit evaluations of its customers and adjusts credit limits, as determined by a review of current credit information. We continuously monitor collection and payments from customers and maintain an allowance for credit losses based upon historical experience, anticipation of uncollectible accounts receivable and any specific customer collection issues that have been identified. While our credit losses have historically been low and within expectations, we may not experience the same credit loss rates that have historically been attained in the future. The receivables are highly concentrated in a relatively small number of customers. Therefore, a significant change in the liquidity, financial position, or willingness to pay timely, or at all, of any one of our significant customers would have a significant impact on our results of operations and cash flows. When determining the reserve for credit losses, we take into consideration current and future economic conditions and the impact that these changing dynamics may have on potential future losses.
The timing between recognition of revenue for product sales and the receipt of payment is not significant. The Company’s standard credit terms, which vary depending on the customer, range between 30 and 60 days. We provide an allowance for credit losses related to our accounts receivable for which collection is doubtful in accordance with ASU 2016-13. In accordance with FASB ASC Topic 326, “Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, (“ASC 326”), we present financial assets at the net amount expected to be collected, requiring immediate recognition of estimated credit losses expected to occur over the asset’s remaining life.
Prompt-pay discounts are offered to some customers; however, due to the uncertainty of the customers taking the discounts, the discounts are recorded when they are taken.
|
10. |
Marketable Securities |
The Company’s marketable securities include investments in equity mutual funds, United States Treasury Bills (“U.S. Treasury Bills”) and Certificates of Deposit with maturities longer than 3 months. Our marketable equity securities are reported at fair value with the related unrealized and realized gains and losses included in net income. U.S Treasury Bills and Certificates of Deposit are recorded at amortized cost. Realized gains or losses on mutual funds are determined on a specific identification basis. We evaluate our investments periodically for possible other-than-temporary impairment by reviewing factors such as the length of time and extent to which fair value had been below cost basis, the financial condition of the issuer and our ability and intent to hold the investment for a period of time which may be sufficient for anticipated recovery of market value.
The disaggregated net gains and losses on the marketable securities recognized in the income statements for the three and nine months ended September 30, 2025 and 2024, respectively, are as follows:
|
Three months ended |
Nine months ended |
|||||||||||||||
|
2025 |
2024 |
2025 |
2024 |
|||||||||||||
|
Net gains recognized during the period on marketable securities |
$ | $ | $ | $ | ||||||||||||
|
Less: Net losses recognized during the period on marketable securities sold during the period |
||||||||||||||||
|
Unrealized gains recognized during the reporting period on marketable securities still held at the reporting date |
$ | $ | $ | $ | ||||||||||||
The fair values of the Company’s marketable securities are determined in accordance with US GAAP, with fair value being defined as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the Company utilizes the three-tier value hierarchy, as prescribed by US GAAP, which prioritizes the inputs used in measuring fair value as follows:
• Level 1 - inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.
• Level 2 - inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.
• Level 3 – inputs to the valuation methodology are unobservable and significant to the fair value measurement.
The Company’s marketable equity securities, which are considered available for sale securities, are re-measured to fair value on a recurring basis and are valued using Level 1 inputs using quoted prices (unadjusted) for identical assets in active markets. The Company’s fixed income U.S. Treasury Bills and Certificates of Deposit are considered held-to-maturity securities and are valued at amortized cost.
The following tables summarize the Company’s investments:
September 30, 2025(Unaudited)
| Cost | Fair Value | Unrealized Gain | ||||||||||
|
Equity Securities: |
||||||||||||
|
Equity and other mutual funds |
$ | $ | $ | |||||||||
|
Other short-term investments: |
||||||||||||
|
U.S. Treasury Bills (original maturities > 3 months) |
- | |||||||||||
|
Total marketable securities |
$ | $ | $ | |||||||||
December 31, 2024(Audited)
| Unrealized Gain | ||||||||||||
|
Equity Securities: |
||||||||||||
|
Equity and other mutual funds |
$ | $ | $ | |||||||||
|
Other short-term investments: |
||||||||||||
|
Fixed income Certificates of Deposit (original maturities > 3 months) |
- | |||||||||||
|
U.S Treasury Bills (original maturities > 3 months) |
- | |||||||||||
|
Total other short-term investments |
- | |||||||||||
|
Total marketable securities |
$ | $ | $ | |||||||||
Investment income is recognized when earned and consists principally of dividend income from equity mutual funds and interest income from U.S. Treasury Bills, Certificates of Deposit and money market funds. Realized gains and losses on sales of investments are determined on a specific identification basis.
Proceeds from the sale and redemption of marketable securities amounted to $
|
11. |
Inventories |
|
September 30, |
December 31, |
|||||||
|
2025 |
2024 |
|||||||
|
(UNAUDITED) |
(AUDITED) |
|||||||
|
Inventories consist of the following: |
||||||||
|
Raw materials |
$ | $ | ||||||
|
Work in process |
||||||||
|
Finished products |
||||||||
|
Total inventories |
$ | $ | ||||||
Inventories are valued at the lower of cost and net realizable value. Net realizable value is equal to the selling price less the estimated costs of selling and/or disposing of the product. Cost is determined using the average cost method, which approximates cost determined by the first-in, first-out (“FIFO”) method. Finished product inventories at September 30, 2025 and December 31, 2024 are stated net of a reserve of $
|
12. |
Income Taxes |
The Company’s tax provision is based on its estimated annual effective tax rate. The Company continues to fully recognize its tax benefits, and as of September 30, 2025 and December 31, 2024, the Company did not have any unrecognized tax benefits. The Company’s provision for income taxes for the three and nine months ended September 30, 2025 and 2024 includes the following:
| Three months ended | Nine months ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
|
Provision for federal income taxes - current |
$ | $ | $ | $ | ||||||||||||
|
Provision for state income taxes - current |
||||||||||||||||
|
(Benefit from) provision for federal income taxes – deferred |
( |
) | ( |
) | ( |
) | ||||||||||
|
Total provision for income taxes |
$ | $ | $ | $ | ||||||||||||
|
13. |
Defined Contribution Plan |
The Company sponsors a 401(k) defined contribution plan (“DC Plan”) that provides for a dollar-for-dollar employer matching contribution of the first
The Company also makes discretionary contributions to each employee's account based on a "pay-to-pay" safe-harbor formula that qualifies the 401(k) Plan under current IRS regulations. Employees become vested in the discretionary contributions as follows:
The Company accrued $
| 14. |
Related-Party Transactions |
The Company’s consulting agreement with Ken Globus, its former President, expired on May 31, 2024 and there were no consulting related payments to Mr. Globus during the three- and nine-month periods ended September 30, 2025. For the three-month period ended September 30, 2024,
For the three-and nine-month periods ended September 30, 2025, the Company made payments of $9,640 and $
|
15. |
Other Information |
Accrued Expenses
Accrued expenses consist of the following:
|
September 30, 2025 |
December 31, 2024 |
|||||||
| Accrued Expenses | (Unaudited) | (Audited) | ||||||
|
Bonuses |
$ | $ | ||||||
|
Distribution fees |
||||||||
|
Payroll and related expenses |
||||||||
|
Reserve for outdated material |
||||||||
|
Company 401(k) contribution |
||||||||
|
Audit fee |
||||||||
|
Annual report expenses |
||||||||
|
Sales rebates |
||||||||
|
Insurance |
||||||||
|
Other |
||||||||
|
Total Accrued Expenses |
$ | $ | ||||||
|
16. |
Recent Accounting Pronouncements |
On July 30, 2025, the FASB issued ASU 2025-05, which amends ASC 326-20 “Financial Instruments – Credit Losses” to provide a practical expedient (for all entities) and an accounting policy election (for all entities, other than public business entities that elect the practical expedient) related to the estimation of expected credit losses for current accounts receivable and current contract assets that arise from transactions accounted for under ASC 606. Under ASU 2025-05, an entity is required to disclose whether it has elected to use the practical expedient and, if so, whether it has also applied the accounting policy election. This guidance is effective for annual reporting periods beginning after December 15, 2025, and interim reporting periods within those annual reporting periods, with early adoption permitted.
On November 4, 2024, the FASB issued ASU 2024-03 “Disaggregation of Income Statement Expenses” (“DISE”). This guidance requires disaggregation of certain expense captions into specified categories in disclosures within the footnotes to the financial statements. Subsequently issued ASU 2025-01, clarified the effective date of this standard. This guidance is effective for annual reporting periods beginning after December 15, 2026, and for interim periods, within annual reporting periods beginning after December 15, 2027.
In December 2023, the FASB issued ASU 2023-09 “Income Taxes- Improvements to Income Tax Disclosures”. This guidance enhances the transparency and decision usefulness of income tax disclosures. More specifically, the amendments relate to the income tax rate reconciliation and income taxes paid disclosures and require 1) consistent categories and greater disaggregation of information in the rate reconciliation and 2) income taxes paid disaggregated by jurisdiction. This guidance is effective for fiscal years beginning after December 31, 2024. On January 1, 2025, the Company implemented this standard and will apply the guidance under the new standard to include additional disclosures in its annual Form 10-K for the year ended December 31, 2025.
In November 2023, the FASB issued ASU 2023-07, "Improvements to Reportable Segment Disclosures". This amendment requires additional disclosures by public entities, including those with a single reportable segment, to disclose significant segment expenses and other segment items for each reportable segment. The guidance applies to fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. On January 1, 2024, we adopted the new standard and applied the guidance under the new standard to include additional disclosures for our single reportable segment. See note 3 for additional information.
|
17. |
Concentrations of Credit Risk |
Customer concentration - Accounts receivable potentially exposes the Company to concentrations of credit risk. The Company monitors the amount of credit it allows each of its customers, using the customer’s prior payment history and its overall credit worthiness to determine how much credit to allow or whether credit should be given at all. It is the Company’s policy to discontinue shipments to any customer that is substantially past due on its payments. The Company sometimes requires payment in advance from customers whose payment record is questionable. As a result of its monitoring of the outstanding credit allowed for each customer, as well as the fact that the majority of the Company’s sales are to customers whose satisfactory credit and payment record has been established over a long period of time, the Company believes that its credit risk from accounts receivable is low.
For the three months ended September 30, 2025, one of the Company’s cosmetic ingredient distributors, and three of its pharmaceutical distributors, together accounted for
For the nine months ended September 30, 2025, one of the Company’s cosmetic ingredient distributors, and three of its pharmaceutical distributors, together accounted for
|
18. |
Supplier Concentration |
Most of the principal raw materials used by the Company consist of common industrial organic and inorganic chemicals that are available in ample supply from numerous sources. However, there are some raw materials used by the Company that are not readily available or require longer lead times.
For the three months ended September 30, 2025, the Company had three major raw material suppliers that collectively accounted for approximately
For the nine months ended September 30, 2025 the Company had three major raw material suppliers that collectively accounted for approximately
|
19. |
Earnings Per Share |
Basic earnings per share is computed by dividing net income available to common shareholders by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings per share is computed by dividing income available to common shareholders by the weighted-average number of shares of common stock outstanding during the period increased to include the number of additional shares of common stock that would have been outstanding if the potentially dilutive securities had been issued.
Per share basic and diluted earnings were $
|
20. |
Dividends |
On January 27, 2025 the Company’s Board of Directors declared a cash dividend of $
On July 11, 2025, the Company’s Board of Directors declared a cash dividend of $
In addition, for the nine-month period ended September 30, 2025, the Company made payments of $
On January 30, 2024, the Company’s Board of Directors declared a cash dividend of $
On July 10, 2024, the Company’s Board of Directors declared a cash dividend of $
ITEM 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
FORWARD-LOOKING STATEMENTS
You should read the following discussion and analysis in conjunction with our financial statements and related notes contained elsewhere in this Quarterly Report. This discussion contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of a variety of factors discussed in this report and those discussed in other documents we file with the SEC. In light of these risks, uncertainties and assumptions, readers are cautioned not to place undue reliance on such forward-looking statements. These forward-looking statements represent beliefs and assumptions as of the date of this report. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change. Past performance does not guarantee future results.
EXECUTIVE OVERVIEW
We specialize in manufacturing cosmetic ingredients, pharmaceuticals, medical lubricants, and sexual wellness ingredients through our Guardian Laboratories division. With a long-standing reputation for delivering high-quality specialty products, we are committed to serving diverse markets with innovative solutions.
As part of our strategic focus, in October 2023, we took a significant step toward expanding our presence in the sexual wellness market by partnering with Brenntag Specialties, a global leader in chemicals and ingredients distribution. Under this agreement, Brenntag began marketing and distributing our new Natrajel line of sexual wellness ingredients in the United States, Canada, Mexico, Central America, and South America. We had expected to begin manufacturing and reporting sales of this new line of products in 2025, but manufacturing has been delayed until 2026 due to customer timeline.
We have also expanded our relationship with Azelis Group NV (“Azelis”), our distributor in the United Kingdom (“UK”) and Ireland. The first step was expanding Azelis’s distribution to include our medical products in the UK and Ireland territories. In addition, we have added South Korea as a new territory for them for our personal care product line.
With a strong and growing product portfolio, and to better cope with the potential impact of tariffs and other global economic uncertainties on our business, we have expanded our strategy to include additional growth initiatives. These initiatives include closely monitoring our supply chain to control costs, expanding our distribution network to better serve our customers, seeking opportunities to expand our position in healthcare as well as pursuing external opportunities to grow our business.
CRITICAL ACCOUNTING POLICIES
As disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, the discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been prepared in conformity with US GAAP. The preparation of those financial statements required us to make estimates and assumptions that affect the carrying value of assets, liabilities, revenues, and expenses reported in those financial statements. Those estimates and assumptions can be subjective and complex, and consequently actual results could differ from those estimates and assumptions. Our most critical accounting policies relate to revenue recognition, concentration of credit risk, investments, inventory, and income taxes. Since December 31, 2024, there have been no significant changes to the assumptions and estimates related to those critical accounting policies.
The following discussion and analysis cover material changes in our financial condition since the year ended December 31, 2024, and a comparison of the results of operations for the three and nine months ended September 30, 2025 and September 30, 2024. This discussion and analysis should be read in conjunction with “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in our Annual Report on Form 10-K for the year ended December 31, 2024. All references in this quarterly report to “sales” or “Sales” shall mean Net Sales unless specified otherwise.
In accordance with ASU-2016-13, we recognize an allowance for credit losses for financial assets carried at amortized cost to present the net amount expected to be collected as of the balance sheet date. Such allowance is based on the credit losses expected to arise over the life of the asset.
RESULTS OF OPERATIONS
Net Sales
Net sales for the third quarter of 2025 decreased by $795,852 (26%) when compared with the same period in 2024. Net sales for the first nine months of 2025 decreased by $2,121,649 (22%) as compared with the corresponding period in 2024. The decrease in sales for the third quarter of 2025 and the first nine months of 2025 were attributable to changes in sales of the following product lines:
Cosmetic ingredients:
|
(a) |
Third quarter sales: For the third quarter of 2025, the Company’s sales of cosmetic ingredients decreased by $886,186 (69%) when compared with the third quarter of 2024. The decrease in third quarter sales was due primarily to a decrease of $944,083 (77%) in sales of the Company’s cosmetic products to ASI. Based on information provided to the Company by ASI, the majority of the decrease in sales of the Company’s products related to customers in Asia. This was due to (a) economic conditions in China being softer compared to 2024; (b) tariff and geopolitical concerns resulting in significant price issues for Chinese customers, forcing them to seek lower-cost competitive products and (c) ASI working off excess inventory. The impact of tariffs and other geopolitical issues appear to be a short term concern as customers are returning with additional price support. |
Third quarter sales in 2025 to the Company’s four other distributors, as well as to two direct cosmetic ingredient customers, increased by a net of $57,897 (86%) compared with the third quarter of 2024. This sales increase was primarily due to increases in sales to our distributors in France and the United Kingdom.
|
(b) |
Nine-month sales: For the first nine months of 2025, the Company’s sales of cosmetic ingredients decreased by $2,586,495 (56%) when compared with the same period in 2024. This decrease was due primarily to a decrease of $2,801,670 (65%) in sales to ASI. Based on information provided to the Company by ASI, the decrease in sales was due to (a) ASI working off excess inventory; (b) economic conditions in China being softer compared to 2024; and (c) tariff and geopolitical concerns resulting in significant price issues for Chinese customers, forcing them to seek lower-cost competitive products. With price support ASI has regained some customers, and we hope to see a turnaround in sales moving forward. |
Cosmetic ingredient sales for the first nine months of the year to the Company’s four other cosmetic distributors, as well as to two direct cosmetic customers, increased by a net of $215,175 (74%) compared with the same period in 2024. This sales increase was primarily due to the addition of a new distributor in Korea, combined with increases in sales to our distributors in France and the United Kingdom.
Pharmaceuticals:
Because there are fees, rebates and allowances associated with sales of the Company’s two pharmaceutical products, Renacidin and Clorpactin®, discussion of the Company’s pharmaceutical sales includes references to both gross sales (before fees, rebates and allowances) and net sales (after fees, rebates and allowances).
Gross sales of the Company’s pharmaceutical products for the three-and nine-month periods ended September 30, 2025 increased by $146,849 (11%) and $442,805 (11%), respectively. The increase in sales for both periods was due primarily to increases in gross sales of Renacidin of $143,085 (13%) for the three-month period and $490,191 (14%) for the nine-month period.
The Company typically experiences fluctuations in sales of its pharmaceutical products due to the timing of orders from its distributors. The Company has invested in a payer outreach program with the goal of having Renacidin, our most popular pharmaceutical product, included on additional insurance formularies. This project is underway and we have received positive feedback from the value proposition we have presented. We will continue to broaden the awareness of Renacidin with the goal of growing our market share.
Net sales of the Company’s pharmaceutical products for the three- and nine-month periods ended September 30, 2025 saw a similar pattern, increasing by $108,080 (10%) for the three-month period and increasing by $362,480 (10%) for the nine-month period, with those increases due primarily to the reason noted above.
The difference between the change in net sales compared with the change in gross sales for these products is due to a combination of the change in gross sales of those products as well as changes in pharmaceutical sales allowances related to these products. Typically, these allowances have a direct relationship with the sales of the Company’s pharmaceutical products. For the three- and nine-month periods ended September 30, 2025, sales allowances related to the Company’s pharmaceutical products increased by $38,769 (12%) and $80,326 (9%), respectively, which were primarily related to increases in VA rebates and distribution fees.
Medical lubricants:
Sales of the Company’s medical lubricants decreased by $17,746 (3%) for the three-month period ended September 30, 2025, compared with the same period in 2024, while sales for the nine-month period increased by $102,366 (6%), compared with the same period in 2024. The decrease in medical lubricant sales for the three-month period was due to normal ordering patterns. The increase for the nine-month period was primarily attributable to increased orders from two customers in China.
Cost of Sales
Cost of sales as a percentage of sales increased to 58% in the third quarter of 2025, up from 46% in the third quarter of 2024. For the first nine months of 2025, cost of sales as a percentage of sales increased to 50%, up from 47% in 2024. The increases in both periods were the result of the Company’s pharmaceutical sales representing a larger percentage of the Company’s total sales for both the three- and nine-month periods ended September 30, 2025 compared with the same periods in 2024. These products carry a lower gross margin than the Company’s other products. In addition, there were higher per unit overhead costs in 2025, which was the result of decreased production of cosmetic products due to lower demand in 2025 compared to the same periods in 2024.
Operating Expenses
Operating expenses, consisting of selling and general and administrative expenses, increased by $29,846 (5%) for the third quarter of 2025 compared with the equivalent period in 2024 and increased by $184,989 (10%) for the first nine months of 2025, compared with the equivalent period in 2024. The increase in operating expenses for both periods was due primarily to increases in sales and marketing expenses, fees paid to the Company’s Board of Directors, consulting fees and increases in payroll and payroll-related expenses.
Research and Development Expenses
Research and development expenses increased by $6,032 (5%) for the third quarter of 2025, and increased by $13,652 (4%) for the first nine months of 2025 compared with the same periods in 2024. The increases for both periods was primarily due to an increase in payroll and payroll-related expenses.
Investment Income
Investment income decreased by $24,769 (25%) and $67,589 (23%) for the three- and nine-month periods, respectively, ending September 30, 2025, compared with the equivalent periods in 2024. The decrease in both periods was primarily due to a decrease in interest income from investments in U. S. Treasury Bills because of lower interest rates in 2025 compared to 2024, combined with a decrease in the average amount invested during 2025 compared to 2024 due to an increase in cash requirements.
Net Gain on Marketable Securities
The net gain on marketable securities decreased from $47,223 to $36,238 for the quarter ended September 30, 2025 compared to the same period in 2024. For the nine-month period ended September 30, 2025, the net gain decreased from $79,218 to $73,164. These decreased gains were due to normal market fluctuations. The Company’s management and Board of Directors continue to closely monitor the Company's investment portfolio and have made, and will continue to make, any changes they believe may be necessary or appropriate to minimize the future impact of global market volatility on the Company’s financial position.”
Provision for Income Taxes
The Company's effective income tax rate was approximately 20% for the first nine months of 2025 and 2024. The Company’s tax rate is expected to remain at 20% for the current fiscal year.
LIQUIDITY AND CAPITAL RESOURCES
Working capital decreased from $10,751,082 at December 31, 2024 to $9,648,984 at September 30, 2025, a decrease of $1,102,098. The current ratio increased from 6.6 to 1 at December 31, 2024 to 7.0 to 1 at September 30, 2025. The decrease in working capital was primarily due to a decrease in cash and cash equivalents and accounts receivable. The increase in the current ratio was primarily due to decreases in accounts payable and accrued expenses.
The Company believes that its working capital is, and will continue to be, sufficient to support its operating requirements for at least the next twelve months.
The Company has completed the upgrade of its building sprinkler system and has incurred costs of $187,961 to date and expects to make final payments in the amount of $7,160 during the fourth quarter of 2025.
The Company generated cash from operations of $1,636,324 and $3,196,954 for the nine months ended September 30, 2025 and September 30, 2024, respectively. The decrease in cash from operations was primarily due to a decrease in net income, combined with decreases in accounts payable and accrued expenses.
Cash provided by investing activities for the nine-month period ended September 30, 2025 was $115,577. Cash used in investing activities for the nine-month period ended September 30, 2024 was $6,241,837. The fluctuation was due to the fact that during the first nine months of 2024, the Company’s U.S. Treasury Bills with maturities of three months or less matured. These had been classified as cash and cash equivalents due to their short maturity. The proceeds from these maturities were then used to purchase longer term U.S. Treasury Bills, which were then classified as marketable securities.
Cash used in financing activities was $2,766,720 and $2,756,323 for the nine months ended September 30, 2025 and September 30, 2024, respectively. The increase was due a payment made in the second quarter of 2025 in the amount of $10,290, which represented dividends in arrears to shareholders who had either converted their Guardian Chemical shares to United-Guardian, Inc. shares or whose shares had been escheated.
The Company expects to continue to use its cash to make dividend payments, to purchase marketable securities, and to take advantage of growth opportunities that are in the best interest of the Company and its shareholders.
OFF BALANCE-SHEET ARRANGEMENTS
The Company has no off balance-sheet transactions that have, or are reasonably likely to have, a current or future effect on the Company’s financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.
CONTRACTUAL OBLIGATIONS AND COMMITMENTS
The information to be reported under this item is not required of smaller reporting companies.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.
The information to be reported under this item is not required of smaller reporting companies.
ITEM 4. CONTROLS AND PROCEDURES
|
(a) |
DISCLOSURE CONTROLS AND PROCEDURES |
The Company’s management, including its Principal Executive Officer and Chief Financial Officer, has evaluated the design, operation, and effectiveness of the Company’s disclosure controls and procedures pursuant to Rule 13a-15 under the Securities Exchange Act of 1934 (the “Exchange Act”). There are inherent limitations to the effectiveness of any system of disclosure controls and procedures, including the possibility of human error and the circumvention or overriding of the controls and procedures. Accordingly, even effective disclosure controls and procedures can only provide reasonable assurance of achieving their control objectives. Based upon the evaluation performed by the Company’s management, including its Principal Executive Officer and Chief Financial Officer, it was determined that, as of the end of the period covered by this quarterly report, the Company’s disclosure controls and procedures were effective in providing reasonable assurance that information required to be disclosed in the reports filed or submitted pursuant to the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the SEC, and that such information is accumulated and communicated to the Company’s management, including its Principal Executive Officer and Chief Financial Officer, or persons performing similar functions, as appropriate, to allow timely decisions regarding disclosures.
|
(b) |
CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING |
The Company's Principal Executive Officer and Chief Financial Officer have determined that, during the period covered by this quarterly report, there were no changes in the Company's internal control over financial reporting that materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting. They have also concluded that there were no significant changes in the Company’s internal controls after the date of the evaluation.
PART II - OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
NONE
ITEM 1A. RISK FACTORS
Impact of Global Supply Chain Instability, Inflation and Tariffs
The Company is actively monitoring trade policy and tariff announcements including executive orders issued by the executive branch of the United States (“U.S.”) federal government regarding tariffs on imports from various countries, with a focus on China, as these tariffs and any reciprocal actions by the Chinese government could have the greatest potential to significantly impact our business. We are also monitoring the potential impact of actions taken by other countries in response to the announced tariffs. While many countries have reached agreements with the U.S., China announced on August 12, 2025 that they have agreed to maintain their retaliatory tariff rate at 10% until November 10, 2025. Based on a recent meeting between the U.S. and China, negotiations for a one-year truce has been established which lowers the tariffs imposed on China but it is unclear if the retaliatory tariff will be modified. We are still in discussions with one of our distributors on how we may be able to help mitigate the financial impact of their shipments of our products into China. These discussions are ongoing and subsequently may change based on the outcome of the U.S. and China negotiations; however no definitive agreement has been reached at this time. It is also unclear at this time if additional retaliatory tariffs will be imposed and what impact they will have on our business. We will continue to monitor the situation closely.
A significant amount of our cosmetic ingredient and medical lubricant sales are reliant on shipments to China. If significant tariffs or other restrictions are placed on Chinese imports, or any countermeasures are taken by China, our business, financial condition or results of operations could be materially and adversely affected. Such tariffs may make our products less cost competitive and reduce gross margins, especially in China, where we face significant competition from Asian companies that manufacture and sell products that are competitive with our products. Furthermore, we may not be able to increase our prices for our products enough to offset these tariffs, and if we raise prices in response to these tariffs, demand for our products in certain regions may be reduced. The impact of the softened demand in China due to these tariffs was reflected in the sales of our cosmetic products during the first nine months of 2025.
Many of our products are used in the formulation of finished products that are manufactured in China and then imported back into the U.S. for sale. There is the possibility that the tariffs levied on these finished products could result in an increase in their price, which could potentially impact demand for these products in the U.S. There is also a possibility that customers will consider moving their manufacturing from China as a strategic decision to limit the impact from tariffs. We have strong global relationships with our distributors and will continue to work together to understand how tariffs are impacting their business.
We source products through numerous suppliers, many of whom have established long-term relationships with us. While we obtain most of our raw materials and lab supplies from domestic sources, we have three suppliers that obtain their raw materials from China. These materials are not purchased by us in large quantities, and we have adequate stock on hand to cover the next six months. In addition, we have one direct raw material supplier in China; however, we do not purchase large quantities of raw materials from this supplier, and the effect of this tariff would not materially impact the pricing of our products.
At this time, the overall impact on our business related to these or any other tariffs that may be imposed, remains uncertain and depends on multiple factors, including the duration and expansion of current tariffs, future changes to tariff rates, scope or enforcement, retaliatory measures by impacted trade partners, inflationary effects, and the effectiveness of our responses in managing these challenges.
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
NONE
ITEM 3. DEFAULTS UPON SENIOR SECURITIES
NONE
ITEM 4. MINE SAFETY DISCLOSURES
NONE
ITEM 5. OTHER INFORMATION
NONE
ITEM 6. EXHIBITS
|
31.1* |
Certification of Donna Vigilante, President and Principal Executive Officer of the Company, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |
|
31.2* |
Certification of Andrea Young, Chief Financial Officer of the Company, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |
|
32* |
Certifications of Principal Executive Officer and Chief Financial Officer of the Company, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
|
101.INS* |
Inline XBRL Instance Document – The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the inline XBRL document. |
|
101.SCH* |
Inline XBRL Taxonomy Extension Schema Document. |
|
101.CAL* |
Inline XBRL Taxonomy Extension Calculation Linkbase Document. |
|
101.DEF* |
Inline XBRL Taxonomy Extension Definition Linkbase Document. |
|
101.LAB* |
Inline XBRL Taxonomy Extension Label Linkbase Document. |
|
101.PRE* |
Inline XBRL Taxonomy Extension Presentation Linkbase Document. |
|
104* |
Cover Page Interactive Data File (Embedded within the inline XBRL document and included in Exhibit 101.1). |
* Filed herewith
SIGNATURES
In accordance with the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
Date: November 4, 2025 |
UNITED-GUARDIAN, INC. |
|
(Registrant) |
|
|
By: /S/ DONNA VIGILANTE |
|
|
Donna Vigilante |
|
|
President |
|
|
By: /S/ ANDREA YOUNG |
|
|
Andrea Young |
|
|
Chief Financial Officer |
FAQ
How did United-Guardian (UG) perform in Q3 2025?
What were UG’s results for the first nine months of 2025?
What drove margin changes at UG in Q3 2025?
How exposed is UG to China and tariffs?
Did UG pay dividends in 2025?
What was UG’s operating cash flow year-to-date?
What is the status of the Natrajel product line?
